Navigation Links
Gerresheimer Sets up New Production Facility for Insulin Pen Systems in Brazil
Date:1/11/2010

    DUSSELDORF, Germany, January 11 /PRNewswire-FirstCall/ --
    - Expansion of Cooperation With Diabetes Leader Novo Nordisk
    - Important Step in the Worldwide Development of Medical Plastic Systems

The Gerresheimer Group has set up a new facility for medical plastic systems in Indaiatuba (Brazil). The plant is to commence operations early in 2010. On the basis of a long-term cooperation agreement with Novo Nordisk, components will be produced with state-of-the-art technology for insulin pen systems for diabetics.

Insulin pens are drug-delivery devices in ball-point pen format which allow diabetes patients to inject themselves with the regularly required insulin dose safely and almost painlessly. Novo Nordisk as the world's leading insulin producer has contracted Gerresheimer to manufacture components for its insulin pens. Novo Nordisk has a large insulin plant in Brazil which will in future be supplied locally by the new technology center of the Gerresheimer Group. For Gerresheimer this is already the fourth production plant in South America in addition to two existing plants for standardized pharma plastic packaging in Brazil and one in Argentina.

Apart from the new production facility in Brazil, Gerresheimer already has two other production facilities for pen systems in Europe.

"Cooperation with Novo Nordisk in Brazil is of substantial strategic importance for us. We support the customer in developing new markets and at the same time expand our technological base in South America," says Gerresheimer CEO Dr. Axel Herberg.

About Gerresheimer

Gerresheimer employs around 10,000 people in 40 locations in Europe, America and Asia. In the financial year 2008, worldwide sales totaled EUR1.06bn. The product portfolio ranges from pharma-ceu-tical vials made of glass and plastic through to complex drug-delivery systems for the pharma & hea
'/>"/>

SOURCE Gerresheimer AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Gerresheimer Holds its own in Difficult Environment
2. Gerresheimer Sells Technical Plastics Business
3. Gerresheimer Opens New High-Tech Production Facility for Pharma Glass in China
4. 2008 a Record Year for Gerresheimer
5. Following a Record Year in 2008 Gerresheimer Again Sets its Sights on Substantial Growth in 2009
6. Gerresheimer Substantially Increases Quarterly Operating Profit
7. Gerresheimer Starts Process to Sell off its Business Segment of Technical Plastics
8. Gerresheimer Further Increases its Sales and Earnings Power
9. Gerresheimer Discontinues Marginal Operations
10. Moodys Raises Rating for Gerresheimer
11. Gerresheimer: Record Year in 2007 and Positive Outlook for 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... (PRWEB) April 16, 2015 Proove ... Buzz of BIO Contest for the 2015 ... (BIO), the 2015 BIO International Convention will take place ... Pennsylvania. During the Buzz of BIO contest, industry leaders ... see present at the conference. The community voting period ...
(Date:4/16/2015)... OncoTAb, Inc., a University ... company, announced today the appointment of physician and ... Operating Officer (COO). Cooper brings to OncoTAb more ... diagnostic and biotechnology platforms in the fields of ... career transcends the field of medical and scientific ...
(Date:4/16/2015)... April 16, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... U.S. joint venture with G-treeBNT (ReGenTree LLC) has ... clinical trial for the orphan disorder, neurotrophic keratopathy ... dry eye syndrome (DES) in the U.S.  Both ... RGN-259/GBT201, this year.  Each of these eye disorders ...
(Date:4/16/2015)... 16, 2015  AnaptysBio, Inc., a leader in ... today announced the advancement of its first-in-class ... studies. The Company,s anti-IL-36R therapeutic antibody, called ... pustular psoriasis (GPP), an orphan systemic inflammatory ... wholly owned within AnaptysBio,s proprietary antibody pipeline ...
Breaking Biology Technology:Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 2Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 3OncoTAb Names Dr. David L. Cooper as COO 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2
... PARK, N.C., Jan. 14, 2011 Talecris Biotherapeutics Holdings Corp. ... established a new record date and meeting date for the ... merger agreement under which Grifols (GRF.MC) will acquire TLCR. ... on January 11, 2011 will be entitled to vote at ...
... now open for StemCONN 2011. The full-day ... cell research, will take place Tuesday, March 22, in ... the UConn Health Center (commercial session and tour). ... http://stemconn.org/ . StemCONN 2011 will feature a ...
... reversal of tinnitus, a debilitating hearing impairment affecting at ... 40 percent of military veterans, according to an article ... Nature . Researchers Dr. Michael Kilgard and ... Dallas and University-affiliated biotechnology firm MicroTransponder report that stimulation ...
Cached Biology Technology:Nature article focuses on tinnitus treatment 2Nature article focuses on tinnitus treatment 3
(Date:4/14/2015)...  HYPR Corp. today announced it has joined ... tm , an industry consortium transforming online authentication ... technology and collaborate to deliver open specifications for ... and private, and easier to use. ... sensitive user information and eliminates the dependency on ...
(Date:4/9/2015)... Calif. , April 9, 2015 Synaptics ... interface solutions, announced today that it will report financial ... Thursday, April 23, 2015, after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
(Date:4/2/2015)... April 2, 2015 According to ... attributed to somewhat higher than 125 MSEK. This exceeds ... report 2014 that revenues for Q1 2015 would be ... reported for Q4 2014. The operating result for the ... The complete interim report will as previously communicated be ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2
... Ecology drives evolution. In today,s issue of the journal ... growing evidence that the reverse is also true, and ... how environmental change affects species and vice-versa. A ... a Galpagos ground finch, Geospiza fortis. In this species, ...
... available in French . , Montreal, January 28, 2011 ... a rare form of cancer that caused a strange combination of ... his stomach and colon. His medical team was stumped and was ... family: the cause of his disease and the risk for future ...
... University of the Negev (BGU) and the PTT Chemical ... research and development collaboration agreement for commercial development of ... for the production of dihomo gamma-linolenic acid (DGLA- Omega ... Parietochloris incise. The joint research will focus on optimizing ...
Cached Biology News:Cold cases gone hot: Montreal researchers solve decades-old medical mysteries using genetics 2Ben-Gurion U. and PTT Chemical sign R&D agreement to commercialize green algae strain 2
... & visualization software. See ... samples. Combine Sequest and ... confidence. Get more detailed ... your MS/MS experiments.14 day ...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
...
...
Biology Products: